» Articles » PMID: 22356587

Increase in Fecal Primary Bile Acids and Dysbiosis in Patients with Diarrhea-predominant Irritable Bowel Syndrome

Overview
Date 2012 Feb 24
PMID 22356587
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Irritable bowel syndrome (IBS) is a multifactorial disease for which a dysbiosis of the gut microbiota has been described. Bile acids (BA) could play a role as they are endogenous laxatives and are metabolized by gut microbiota. We compared fecal BA profiles and microbiota in healthy subjects (HS) and patients with diarrhea-predominant IBS (IBS-D), and we searched for an association with symptoms.

Methods: Clinical features and stool samples were collected in IBS-D patients and HS. Fecal BA profiles were generated using HPLC coupled to tandem mass spectrometry. The fecal microbiota composition was assessed by q-PCR targeting dominant bacterial groups and species implicated in BA transformation.

Key Results: Fourteen IBS-D patients and 18 HS were included. The two groups were comparable in terms of age and sex. The percentage of fecal primary BA was significantly higher in IBS-D patients than in HS, and it was significantly correlated with stool consistency and frequency. Fecal counts of all bacteria, lactobacillus, coccoides, leptum and Faecalibacterium prausnitzii were similar. There was a significant increase of Escherichia coli and a significant decrease of leptum and bifidobacterium in IBS-D patients.

Conclusions & Inferences: We report an increase of primary BA in the feces of IBS-D patients compared to HS, correlated with stool consistency and frequency. A dysbiosis of different bacterial groups was detected, some of them involved in BA transformation. As the gut microbiota is the exclusive pathway to transform primary into secondary BA, this suggests a functional consequence of dysbiosis, leading to lower BA transformation.

Citing Articles

Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).

Uriot O, Deschamps C, Scanzi J, Brun M, Kerckhove N, Duale C Bioengineered. 2025; 16(1):2458362.

PMID: 39902883 PMC: 11796540. DOI: 10.1080/21655979.2025.2458362.


Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review.

Iribarren C, Maasfeh L, Ohman L, Simren M Gut Microbiome (Camb). 2024; 3:e7.

PMID: 39295774 PMC: 11406401. DOI: 10.1017/gmb.2022.6.


Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption.

Karhus M, Sonne D, Thomasen M, Ellegaard A, Holst J, Rehfeld J Gastro Hep Adv. 2024; 1(3):299-312.

PMID: 39131668 PMC: 11307667. DOI: 10.1016/j.gastha.2021.12.007.


Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial.

Yang N, Ma T, Xie Y, Li Q, Li Y, Zheng L Nat Commun. 2024; 15(1):6823.

PMID: 39122704 PMC: 11315937. DOI: 10.1038/s41467-024-51094-2.


Fecal Microbiota Characteristics in Constipation-Predominant and Mixed-Type Irritable Bowel Syndrome.

Gryaznova M, Smirnova Y, Burakova I, Morozova P, Lagutina S, Chizhkov P Microorganisms. 2024; 12(7).

PMID: 39065182 PMC: 11278693. DOI: 10.3390/microorganisms12071414.